Robert E. Waltermire, Senior VP, Chief Pharma Development at MADRIGAL PHARMACEUTICALS, INC. (MDGL), sold 26,926 shares at $342.90 ($9.2M) on 2025-03-05, disclosed to the SEC on 2025-03-07.
Open-market sale of $9.2M MDGL by Senior VP, Chief Pharma Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $335.15 | 900 | $302K | 3.3% |
| 2 | $336.78 | 1,777 | $598K | 6.5% |
| 3 | $336.78 | 1,777 | $598K | 6.5% |
| 4 | $338.09 | 1,146 | $387K | 4.2% |
| 5 | $338.09 | 1,146 | $387K | 4.2% |
| 6 | $339.68 | 400 |
| $136K |
| 1.5% |
| 7 | $340.75 | 1,657 | $565K | 6.1% |
| 8 | $340.75 | 1,657 | $565K | 6.1% |
| 9 | $341.84 | 1,043 | $357K | 3.9% |
| 10 | $341.84 | 1,043 | $357K | 3.9% |
| 11 | $342.90 | 1,077 | $369K | 4.0% |
| 12 | $342.90 | 1,077 | $369K | 4.0% |
| 13 | $343.85 | 4,701 | $1.6M | 17.6% |
| 14 | $343.85 | 4,701 | $1.6M | 17.6% |
| 15 | $344.76 | 1,412 | $487K | 5.3% |
| 16 | $344.76 | 1,412 | $487K | 5.3% |
| Total | $341.56 avg | 26,926 | $9.2M | 100% |
| Filing → |
| MDGL | SELL | 2025-01-17 | $242K | — | Filing → |
| MDGL | SELL | 2024-06-18 | $532K | — | Filing → |
| MDGL | SELL | 2024-06-14 | $570K | — | Filing → |